Vectus Biosystems Limited
Vectus Biosystems Limited is a drug discovery and development company based in North Ryde, Sydney. Using its platform technology, Vectus has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties.
Fibrosis, the formation of excess fibrous connective tissue in an organ, plays a role in more than 40% of deaths worldwide. This figure includes different diseases affecting the heart, lungs, kidneys and liver, among others. While current treatments only slow the progression of fibrosis, Vectus has demonstrated in animal models that its compounds can reverse the process, leading to the restoration of normal tissue architecture.
To-date, Vectus has identified drug targets with specific activity in the heart, kidneys, lungs and liver. The Company’s lead compound, VB0004, has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. Vectus also aims to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases.
Accugen is a platform, developed by Vectus’ wholly-owned subsidiary, Accugen Pty Limited, comprising reagents and software that quantitate qPCR reactions, i.e. it measures the amount of DNA or RNA in a sample. Vectus believes the Accugen system potentially offers a time, cost and accuracy benefit to more easily and precisely quantify PCR compared to currently available systems. More information can be found on the Accugen website here.